Despite improvements in prevention of graft-versus-host disease, chronic GVHD still occurs in 10%-50% of patients who undergo an allogeneic hematopoietic stem cell transplant, and these patients may require prolonged treatment with multiple lines of therapy, said a hematologist and transplant researcher. “More effective, less toxic therapies for chronic GVHD are needed,” Stephanie Lee, MD, MPH, […]